Pfizer announced positive results from its Phase 2b clinical trial. Notably, its ultra-long-acting injectable GLP-1 receptor agonist produced significant weight loss as part of an innovative obesity treatment. The VESPER 3 study showed that monthly dosing maintained and enhanced weight reduction. Therefore, this approach offers a potential new option for people seeking effective obesity care.
Pfizer designed the VESPER 3 study to test whether PF-3944 could maintain weight loss while switching from weekly to monthly administration. Importantly, the Phase 2b trial met its primary endpoint. Weight reductions were statistically significant compared to placebo at 28 weeks, highlighting the drug’s potential as an effective obesity treatment.
In this randomized, double-blind, placebo-controlled study, adults with obesity or overweight, but without type 2 diabetes, received weekly doses of PF-3944 for up to 12 weeks. Subsequently, they switched to once-monthly dosing through week 28. All four PF-3944 dosing regimens outperformed placebo in mean weight loss, and p-values indicated strong statistical significance.
Interim results showed that two maintenance dosing regimens achieved up to 12.3?percent mean placebo-adjusted weight loss by week 28. Moreover, weight loss continued even after switching regimens. These findings suggest that longer follow-up could produce even greater reductions as the study continues to 64 weeks.
PF-3944 also demonstrated a safety profile similar to other GLP-1 receptor agonists. Gastrointestinal side effects, such as nausea and vomiting, were generally mild or moderate. Additionally, no severe diarrhea cases occurred. Only a small number of participants discontinued treatment due to adverse events in both the weekly and monthly phases.
“Our Phase 2b VESPER 3 results reinforce PF-3944’s potential as a monthly obesity treatment with competitive efficacy and tolerability,” said Jim List, Pfizer’s Chief Internal Medicine Officer. Furthermore, he added that the company plans to include a higher 9.6?mg monthly dose in Phase 3, expanding treatment options for patients.
VESPER 3’s design and results support continued development of PF-3944 across a broad clinical program. Pfizer plans to start or expand at least 10 Phase 3 studies in 2026. These studies, in turn, will include weekly and monthly dosing in adults with obesity or overweight, with and without type 2 diabetes. Future trials will also target obesity-related comorbidities and aim to improve options for patients and clinicians.
Pfizer’s acquisition of Metsera, combined with a global collaboration with YaoPharma, shows the company’s commitment to advancing obesity treatment. The expanded portfolio includes both injectable and oral candidates. In particular, these target GLP-1 receptors, glucose-dependent insulinotropic polypeptide receptors, and amylin analogs. The broad pipeline addresses unmet needs in obesity care and, consequently, aims to help more patients achieve durable weight loss.
Obesity remains a growing global health challenge. In 2015, about 1.9?billion adults were overweight or living with obesity. By 2030, this number is expected to exceed 2.9?billion. As a result, obesity is linked to over 200 health complications, increased mortality risk, and significant socioeconomic burdens. This underscores the need for effective obesity treatment innovations.
Continuous research in obesity therapies has transformed treatment, especially with GLP-1 receptor agonists that produce meaningful weight loss. However, patient adherence and dosing convenience remain challenges. Long-acting monthly options like PF-3944 could help overcome these barriers.
Experts suggest that less frequent dosing may improve adherence and convenience. Many approved therapies require weekly administration. Consequently, monthly dosing could enhance patients' quality of life and broaden options for people struggling with obesity.
Pfizer will present detailed VESPER 3 data at the 86th Scientific Sessions of the American Diabetes Association in June 2026. This presentation will provide the medical community with deeper insights into efficacy and safety outcomes for this promising obesity treatment candidate.
With positive Phase 2b results driving momentum, PF-3944 is poised to become a cornerstone of next-generation obesity treatments. Indeed, it prioritizes both efficacy and patient-friendly dosing.
